EY: 65% of Healthcare Organizations Have Seen a Positive Return on Health Equity Efforts
A new report from Ernst & Young revealed that healthcare organizations are seeing financial benefits and improved outcomes from their health equity strategies.
Report: Sales, financing slow down for medtech firms
The industry faces challenges from inflation to labor shortages, according to an annual report from EY. However, there are grounds for optimism and areas to focus on, such as patching up supply chains.
As Healthcare and Biopharma Companies Embrace AI, Insurance Underwriters See Risks and Opportunities
In an interview, Munich Re Specialty Senior Vice President Jim Craig talked about the risk that accompanies innovation and the important role that insurers play.
Report: Medtech M&A jumps as companies bounce back from the pandemic
Medical technology companies saw 288 deals between June 2020 and June 2021, the highest amount ever since Ernst & Young began tracking it in 2007. VC funding in medtech also reached a high point of $9.1 billion.
Healthcare organizations are advancing their tech initiatives in these areas
An EY survey of 347 physicians and healthcare executives found respondents have undertaken staff satisfaction-related projects and are planning initiatives around analytics.
What are healthcare organizations’ biggest challenges this year?
Hospitals and health systems face multiple challenges as they transition away from fee-for-service models and toward value-based care. A new survey from EY dug deeper into this issue.
#BIO2017 kicks off with a new report highlighting the industry’s resilience
Despite reimbursement, regulatory, and political uncertainty, the global biotech industry held steady in 2016, according to a new report by professional services firm EY (formerly Ernst & Young).
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
5 must-read stories this week: Biotech boom slows, J-Law to play Elizabeth Holmes
Plus, coverage of BIO 2016, progress on health IT interoperability and a fundraise for a concierge care startup.
Is the biotech boom slowing down?
As Ernst & Young noted on several occasions, the biotech sector has matured and must now face adult problems.
EY Report: With early stage investing stifled, things look grim for the medical device industry
The lack of innovation in the medical device industry can be attributed to the lessening dollars being funneled into startups, a new report from Ernst & Young says.
Big Pharma’s big pinch: a $50 billion “growth gap” and fierce M&A competition
Diminished resources and fierce competition from growing biotech and specialty pharma companies will drive smaller and more selective M&A deals by Big Pharma companies in 2013 and beyond. That’s the thesis that Ernst & Young’s life sciences team put forth in a new report called Closing the gap? Big pharma’s growth challenges and implications for […]
presented by
RCM Outsourcing: Balancing Human Expertise & Smart Technology
Greenway Health blends smart technology with human expertise to elevate revenue cycle.
LifeScience Alley conference kicks off amid storm, both literal and figurative
The medical device industry, long the backbone of Minnesota's high tech economy, faces perhaps its most challenging environment in decades. From regulatory headaches and health care reform to a dearth of venture capital, medical device stakeholders face a swirling mix of uncertainty and anxiety.